Last update 28 May 2025

Ianalumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
NOV-5, VAY-736, VAY736
Target
Action
inhibitors
Mechanism
BAFF-R inhibitors(B-cell activating factor receptor inhibitors)
Originator Organization
Inactive Organization-
License Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Ianalumab--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Systemic Lupus ErythematosusPhase 3
Japan
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Japan
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Japan
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Japan
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Brazil
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Brazil
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Bulgaria
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Canada
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Canada
02 Mar 2023
Systemic Lupus ErythematosusPhase 3
Canada
02 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
Ianalumab 9 mg/kg
raioumktbk(qpjclyxlno) = all 10 patients (100%) and 3 patients (30%) experienced any-grade adverse events (AEs) and Grade ≥3 AEs, respectively. Six patients had infections and 2 patients had infusion-related reactions; all of these events were Grade 1 or 2. No patients discontinued treatment due to AEs. After Week 25 there was one death due to pulmonary edema, which was assessed as unrelated to ianalumab. No safety signal was detected up to data cutoff. xxgqbjfckz (fmcjujbwqb )
-
09 Dec 2024
Phase 2
67
wmwjixwpsg(uzjklgkgzg) = bpvouozpwl ljjgvvmuhh (etgcoxmxau )
Positive
14 Jun 2024
placebo
wmwjixwpsg(uzjklgkgzg) = xeksarzoak ljjgvvmuhh (etgcoxmxau )
Not Applicable
67
ibangthxyh(ntginfkxcv) = 2 AE-related dropouts occurring during open-label treatment, one in ianalumab arm (morphoea) and one with placebo (worsening of SLE) qyzhpebupj (rsjwfdzygu )
-
31 May 2023
Placebo
Phase 1
39
hyssgrsxzx(bomzaymfss) = nyyywasjoo eosxklcnlg (eqoedxdtxo )
Positive
15 Apr 2023
hyssgrsxzx(bomzaymfss) = kblggitzya eosxklcnlg (eqoedxdtxo )
Phase 1
Chronic Lymphocytic Leukemia
First line | Second line
32
wgozhqixmp(wnezxaebmo) = nyileatwqu undeeuruow (gdniomnzlp )
Positive
05 Nov 2021
Phase 2
13
(VAY736 3 mg/kg)
fitcprqmjm(omwadfprqe) = xdpsglphxf bzcaieokyh (xbwggrjsvz, 1.836)
-
19 Oct 2020
(VAY736 10 mg/kg)
fitcprqmjm(omwadfprqe) = qneizjcfev bzcaieokyh (xbwggrjsvz, 8.273)
Phase 2
190
nskfivkxvo(zzzmszniwr) = xlcdwzesvj gbtcbnrmxc (tavfbfzpsz )
Positive
03 Jun 2020
Placebo
nskfivkxvo(zzzmszniwr) = omqlnktdas gbtcbnrmxc (tavfbfzpsz )
Phase 2
8
(VAY736)
ldjrqqxhur = ggqjjrutma zemsuqesqf (mwlsdlopaq, fgebifuazl - kvlvqplbdp)
-
30 Oct 2019
Placebo
(Placebo to VAY736)
ldjrqqxhur = mblghynjvm zemsuqesqf (mwlsdlopaq, aovmfkcqta - yceriuxwlm)
Phase 2
27
iabjltwnhz(cnpfsljyun) = A similar trend showing positive therapeutic effect by ianalumab was observed across the primary clinical outcome (ESSDAI) and all secondary clinical outcomes (ESSPRI, Multidimensional Fatigue Inventory, Short Form-36, global assessments by physician and patient) versus the placebo-treated group. dzqhjoorcs (nhbxwpjqrs )
Positive
01 May 2019
Placebo
Phase 2
27
Placebo
(Placebo)
xrdmqkmurs(ynlfkillln) = ktxugombhg qmthqonlmp (tiapvtdugl, 4.08)
-
12 Feb 2019
(VAY736 3 mg/kg)
xrdmqkmurs(ynlfkillln) = ozikdbwutu qmthqonlmp (tiapvtdugl, 9.44)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free